It was reported on Wednesday that United States-based Additive Orthopaedics LLC has received approval from the United States Food and Drug Administration (FDA) for the Patient Specific Talus Spacer 3D-printed talus (ankle bone) implant for humanitarian use.
The product is a 3D printed implant that can be used in talus replacement surgery. The talus spacer is made individually for each patient, modelled from computed tomography imaging, and is fitted to a patient's specific anatomy. The Patient Specific Talus Spacer is claimed to be the first in the world and first-of-its-kind implant to replace the talus, the bone in the ankle joint that connects the leg and the foot, for the treatment of avascular necrosis (AVN) of the ankle joint, a serious and progressive condition that causes the death of bone tissue stemming from a lack of blood supply to the area.
The US FDA has reviewed data for the Patient Specific Talus Spacer via the humanitarian device exemption process.
Privo Technologies reports progress in oral cancer trial
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application